Multiple sclerosis: pharmacogenomics and personalised drug treatment

被引：0
作者：
V. Annibali
G. Ristori
S. Cannoni
S. Romano
A. Visconti
A. Ghazaryan
L. Figà Talamanca
M. Salvetti
R. Mechelli
机构：
[1] Ospedale S. Andrea,Department of Neurology and Centro Neurologico Terapia Sperimentale (CENTERS)
[2] University of Rome “La Sapienza”,undefined
来源：
Neurological Sciences | 2006年 / 27卷
关键词：
Pharmacogenomics; Multiple sclerosis; Therapy; Microarrays;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Multiple sclerosis (MS) is a disorder of the central nervous system with an inflammatory and a neurodegenerative component. We do not yet have a definitive therapy for MS. Attempts to develop new treatments are long and costly and should be paralleled by studies aimed at increasing the therapeutic index of the existing treatments, interferon β and glatiramer acetate. Pharmacogenetics and pharmacogenomics may be of use in this respect though their application may not be straightforward, particularly in MS.
引用
收藏
页码：s347 / s349
相关论文
共 50 条
[41]   Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy [J].
Hamzic, Seida ;
Aebi, Stefan ;
Joerger, Markus ;
Montemurro, Michael ;
Ansari, Marc ;
Amstutz, Ursula ;
Largiader, Carlo .
SWISS MEDICAL WEEKLY, 2020, 150
[42]   Our Health in Our Hands: improving personalised care in multiple sclerosis [J].
Lane, J. ;
Bruestle, A. ;
Lucas, R. ;
Cook, M. ;
Suominen, H. ;
Tricoli, A. ;
Desborough, J. ;
Lueck, C. .
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (03) :NP15-NP16
[43]   An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe [J].
Horgan, Denis ;
Jansen, Marleen ;
Leyens, Lada ;
Lal, Jonathan A. ;
Sudbrak, Ralf ;
Hackenitz, Erica ;
Busshoff, Ulrike ;
Ballensiefen, Wolfgang ;
Brand, Angela .
PUBLIC HEALTH GENOMICS, 2014, 17 (5-6) :287-298
[44]   Treatment of Multiple Sclerosis [J].
Anlar, Omer .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2009, 8 (03) :167-174
[45]   Treatment of multiple sclerosis [J].
Pandit, Lekha ;
Murthy, J. M. K. .
ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2011, 14 :S65-S69
[46]   Rs205764 and rs547311 in linc00513 may influence treatment responses in multiple sclerosis patients: A pharmacogenomics Egyptian study [J].
Amin, Nada Sherif ;
Abd El-Aziz, Mostafa K. ;
Hamed, Mohamed ;
Moustafa, Ramez Reda ;
El Tayebi, Hend M. .
FRONTIERS IN IMMUNOLOGY, 2023, 14
[47]   Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson's Disease. A Perspective [J].
Payami, Haydeh ;
Factor, Stewart A. .
NEUROTHERAPEUTICS, 2014, 11 (01) :111-116
[48]   Development of oral cladribine for the treatment of multiple sclerosis [J].
Hartung, Hans-Peter ;
Aktas, Orhan ;
Kieseier, Bernd ;
Comi, Giancarlo .
JOURNAL OF NEUROLOGY, 2010, 257 (02) :163-170
[49]   2012: Update on diagnosis and treatment of multiple sclerosis [J].
Havla, J. ;
Kuempfel, T. ;
Hohlfeld, R. .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (17) :894-899
[50]   Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards [J].
Warnke, Clemens ;
Kieseier, Bernd C. ;
Hartung, Hans-Peter .
JOURNAL OF NEURAL TRANSMISSION, 2013, 120 :S55-S60
12345